Inozyme Pharma Inc (INZY.O)

+ 收藏

资产负债表(Inozyme Pharma Inc)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2025年一季报2024年年报2024年三季报2024年中报2024年一季报2023年年报2023年三季报2023年中报2023年一季报
截止日期 2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表
报表年结日 123112311231123112311231123112311231
原始币种 美元美元美元美元美元美元美元美元美元
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后上市后上市后
流动资产:
 现金及现金等价物(元) 会员可见会员可见会员可见会员可见20,618,000.0034,588,000.0046,895,000.0040,845,000.0049,024,000.00
 受限制存款及现金流动(元) 会员可见会员可见-------
 预付款项及其他应收款流动(元) 会员可见会员可见会员可见会员可见8,171,000.007,661,000.008,414,000.003,341,000.003,218,000.00
 短期投资(元) 会员可见会员可见会员可见会员可见145,535,000.00154,001,000.00145,547,000.0099,402,000.0081,906,000.00
 流动资产合计(元) 会员可见会员可见会员可见会员可见174,324,000.00196,250,000.00200,856,000.00143,588,000.00134,148,000.00
非流动资产:
 物业、厂房及设备(元) 会员可见会员可见会员可见会员可见1,316,000.001,466,000.001,584,000.001,788,000.001,981,000.00
 受限制存款及现金非流动(元) --会员可见会员可见311,000.00311,000.00311,000.00311,000.00354,000.00
 预付款项及其他长期应收款非流动(元) 会员可见会员可见会员可见会员可见-1,694,000.001,695,000.003,861,000.003,810,000.00
 非流动资产其他项目(元) 会员可见会员可见会员可见会员可见992,000.001,126,000.001,256,000.001,381,000.001,503,000.00
 非流动资产合计(元) 会员可见会员可见会员可见会员可见2,619,000.004,597,000.004,846,000.007,341,000.007,648,000.00
总资产(元) 会员可见会员可见会员可见会员可见176,943,000.00200,847,000.00205,702,000.00150,929,000.00141,796,000.00
流动负债:
 短期债务及长期负债本期部分(元) 会员可见会员可见会员可见------
 融资租赁负债流动(元) 会员可见会员可见会员可见会员可见934,000.00910,000.00886,000.00862,000.00839,000.00
 应付账款及票据(元) 会员可见会员可见会员可见会员可见2,166,000.001,166,000.002,006,000.002,014,000.001,815,000.00
 其他应付款及应计费用(元) 会员可见会员可见会员可见会员可见9,306,000.0012,610,000.009,383,000.009,205,000.009,927,000.00
 流动负债合计(元) 会员可见会员可见会员可见会员可见12,406,000.0014,686,000.0012,275,000.0012,081,000.0012,581,000.00
非流动负债:
 长期债务(元) 会员可见会员可见会员可见会员可见45,032,000.0044,769,000.0032,065,000.0031,877,000.0024,219,000.00
 融资租赁负债非流动(元) --会员可见会员可见669,000.00913,000.001,149,000.001,378,000.001,603,000.00
 非流动负债其他项目(元) --------46,000.00
 非流动负债合计(元) 会员可见会员可见会员可见会员可见45,701,000.0045,682,000.0033,214,000.0033,255,000.0025,868,000.00
总负债(元) 会员可见会员可见会员可见会员可见58,107,000.0060,368,000.0045,489,000.0045,336,000.0038,449,000.00
股东权益:
 普通股(元) 会员可见会员可见会员可见会员可见6,000.006,000.006,000.005,000.004,000.00
 股本溢价(元) 会员可见会员可见会员可见会员可见428,212,000.00426,362,000.00424,671,000.00353,285,000.00335,544,000.00
 留存收益(元) 会员可见会员可见会员可见会员可见-309,277,000.00-285,930,000.00-264,386,000.00-247,748,000.00-232,165,000.00
 累计其他全面收益(元) 会员可见会员可见会员可见会员可见-105,000.0041,000.00-78,000.0051,000.00-36,000.00
 归属于母公司股东权益(元) 会员可见会员可见会员可见会员可见118,836,000.00140,479,000.00160,213,000.00105,593,000.00103,347,000.00
 股东权益合计(元) 会员可见会员可见会员可见会员可见118,836,000.00140,479,000.00160,213,000.00105,593,000.00103,347,000.00
负债及股东权益合计(元) 会员可见会员可见会员可见会员可见176,943,000.00200,847,000.00205,702,000.00150,929,000.00141,796,000.00
公告日期 2025-05-142025-03-102024-11-052024-08-062024-05-072024-03-122023-11-072023-08-082023-05-09
会计准则 美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则
审计意见
核数师

前瞻产业研究院